Sotorasib and Geriatric Use (Data)

In this article, we will discuss Sotorasib and Geriatric Use (Data). So, let’s get started.

Sotorasib and Geriatric Use (Data)

Of the 357 patients with any tumor type who received Sotorasib 960 mg orally once daily in CodeBreaK 100, 46% were 65 and over, and 10% were 75 and over. No overall differences in safety or effectiveness were observed between older patients and younger patients.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.